Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
158,835,667
-
Number of holders
-
234
-
Total 13F shares, excl. options
-
90,107,125
-
Shares change
-
+32,580
-
Total reported value, excl. options
-
$1,370,540,354
-
Value change
-
-$16,725,794
-
Put/Call ratio
-
66%
-
Number of buys
-
115
-
Number of sells
-
-106
-
Price
-
$15.21
Significant Holders of TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) as of Q1 2024
298 filings reported holding TGTX - TG THERAPEUTICS, INC. - COMMON STOCK as of Q1 2024.
TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) has 234 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 90,107,125 shares
of 158,835,667 outstanding shares and own 57% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (13,536,832 shares), BlackRock Inc. (10,843,502 shares), STATE STREET CORP (7,796,579 shares), MILLENNIUM MANAGEMENT LLC (3,484,046 shares), PICTET ASSET MANAGEMENT Holding SA (3,327,214 shares), Soleus Capital Management, L.P. (3,168,456 shares), WELLINGTON MANAGEMENT GROUP LLP (3,153,593 shares), GEODE CAPITAL MANAGEMENT, LLC (3,107,444 shares), Opaleye Management Inc. (2,280,000 shares), and BANK OF AMERICA CORP /DE/ (2,201,450 shares).
This table shows the top 234 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.